Development of cellular signaling pathway inhibitors as new antivirals against influenza

Antiviral Research

Volumn 98, Issue 3, 2013, Pages 457-468

  Planz, Oliver ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Antiviral therapy; Cellular drug targets; Influenza virus; Resistance; Signaling pathways

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ACETYLSALICYLIC ACID; AMANTADINE; ANTIVIRUS AGENT; AZD 8330; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CL 1040; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE ACETYLSALICYLATE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OSELTAMIVIR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; RAF PROTEIN; RDEA 119; SC 75741; SELUMETINIB; UNCLASSIFIED DRUG; VL 01;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BREAST CANCER; CD4+ T LYMPHOCYTE; COLON CANCER; CYTOKINE PRODUCTION; DIARRHEA; DRUG ERUPTION; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATIGUE; HUMAN; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N7; LUNG NON SMALL CELL CANCER; MDCK CELL; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VIRUS REPLICATION; VOMITING;

ANIMALS; ANTIVIRAL AGENTS; BENZAMIDES; BUTADIENES; ENZYME ACTIVATION; HUMANS; INFLUENZA, HUMAN; LEUPEPTINS; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; NITRILES; ORTHOMYXOVIRIDAE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; VIRUS REPLICATION;

ORTHOMYXOVIRIDAE;

EID: 84877613064     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.04.008     Document Type: Review

References (107)

1. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5:417-421.
2. Adams J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 2004, 4:349-360.
3. Adams J., Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004, 22:304-311.
4. Adjei A.A., Cohen R.B., Franklin W., Morris C., Wilson D., Molina J.R., Hanson L.J., Gore L., Chow L., Leong S., Maloney L., Gordon G., Simmons H., Marlow A., Litwiler K., Brown S., Poch G., Kane K., Haney J., Eckhardt S.G. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 2008, 26:2139-2146.
5. Barrett S.D., Bridges A.J., Dudley D.T., Saltiel A.R., Fergus J.H., Flamme C.M., Delaney A.M., Kaufman M., LePage S., Leopold W.R., Przybranowski S.A., Sebolt-Leopold J., Van Becelaere K., Doherty A.M., Kennedy R.M., Marston D., Howard W.A., Smith Y., Warmus J.S., Tecle H. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg. Med. Chem. Lett. 2008, 18:6501-6504.
6. Beigel J.H., Farrar J., Han A.M., Hayden F.G., Hyer R., de Jong M.D., Lochindarat S., Nguyen T.K., Nguyen T.H., Tran T.H., Nicoll A., Touch S., Yuen K.Y. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 2005, 353:1374-1385.
7. Berenson J.R., Yellin O. New drugs in multiple myeloma. Curr. Opin. Support. Palliat. Care 2008, 2:204-210.
8. Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004, 25:280-288.
9. Bosco R., Melloni E., Celeghini C., Rimondi E., Vaccarezza M., Zauli G. Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. Mini Rev. Med. Chem. 2011, 11:185-199.
10. Cao, B., Li, J., Mao, X., 2012. Dissecting bortezomib: development, application, adverse effects and future direction. Curr. Pharm. Des. 2012 Nov 2. [Epub ahead of print].
11. Carracedo A., Pandolfi P.P. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008, 27:5527-5541.
12. Castellano E., Downward J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2011, 2:261-274.
13. Chan M.C., Cheung C.Y., Chui W.H., Tsao S.W., Nicholls J.M., Chan Y.O., Chan R.W., Long H.T., Poon L.L., Guan Y., Peiris J.S. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir. Res. 2005, 6:135.
14. Chapuis N., Tamburini J., Green A.S., Vignon C., Bardet V., Neyret A., Pannetier M., Willems L., Park S., Macone A., Maira S.M., Ifrah N., Dreyfus F., Herault O., Lacombe C., Mayeux P., Bouscary D. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin. Cancer Res. 2010, 16:5424-5435.
15. Cheng X.W., Lu J., Wu C.L., Yi L.N., Xie X., Shi X.D., Fang S.S., Zan H., Kung H.F., He M.L. Three fatal cases of pandemic 2009 influenza A virus infection in Shenzhen are associated with cytokine storm. Respir. Physiol. Neurobiol. 2011, 175:185-187.
16. Chu W.M., Ostertag D., Li Z.W., Chang L., Chen Y., Hu Y., Williams B., Perrault J., Karin M. JNK2 and IKKbeta are required for activating the innate response to viral infection. Immunity 1999, 11:721-731.
17. Cohen R.B., Aamdal S., Nyakas M., Cavallin M., Green D., Learoyd M., Smith I., Kurzrock R. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur. J. Cancer 2013.
18. de Jong M.D., Simmons C.P., Thanh T.T., Hien V.M., Smith G.J., Chau T.N., Hoang D.M., Chau N.V., Khanh T.H., Dong V.C., Qui P.T., Cam B.V., Ha do Q., Guan Y., Peiris J.S., Chinh N.T., Hien T.T., Farrar J. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 2006, 12:1203-1207.
19. Dev A., Iyer S., Razani B., Cheng G. NF-kappaB and innate immunity. Curr. Top. Microbiol. Immunol. 2011, 349:115-143.
20. Droebner K., Pleschka S., Ludwig S., Planz O. Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Res.. 2011, 92:195-203.
21. Dudek S.E., Luig C., Pauli E.K., Schubert U., Ludwig S. The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state. J. Virol. 2010, 84:9439-9451.
22. Ehrhardt C., Ludwig S. A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway. Cell Microbiol. 2009, 11:863-871.
23. Ehrhardt C., Marjuki H., Wolff T., Nurnberg B., Planz O., Pleschka S., Ludwig S. Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence. Cell Microbiol. 2006, 8:1336-1348.
24. Ehrhardt C., Wolff T., Pleschka S., Planz O., Beermann W., Bode J.G., Schmolke M., Ludwig S. Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. J. Virol. 2007, 81:3058-3067.
25. Ehrhardt, C., Ruckle, A., Hrincius, E.R., Haasbach, E., Anhlan, D., Ahmann, K., Banning, C., Reiling, S.J., Kuhn, J., Strobl, S., Vitt, D., Leban, J., Planz, O., Ludwig, S., 2013. The NF-kappaB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistance. Cell Microbiol. 2013 Jan 16. doi: 10.1111/cmi.12108. [Epub ahead of print].
26. Eisenberg S., Shvartsman D.E., Ehrlich M., Henis Y.I. Clustering of raft-associated proteins in the external membrane leaflet modulates internal leaflet H-ras diffusion and signaling. Mol. Cell Biol. 2006, 26:7190-7200.
27. Faleiro L., Lazebnik Y. Caspases disrupt the nuclear-cytoplasmic barrier. J. Cell Biol. 2000, 151:951-959.
28. Fremin C., Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J. Hematol. Oncol. 2010, 3:8.
29. Gilmore T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006, 25:6680-6684.
30. Gilmore T.D., Garbati M.R. Inhibition of NF-kappaB signaling as a strategy in disease therapy. Curr. Top. Microbiol. Immunol. 2011, 349:245-263.
31. Gilmore T.D., Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 2006, 25:6887-6899.
32. Glasgow J.F. Reye's syndrome: the case for a causal link with aspirin. Drug Safety 2006, 29:1111-1121.
33. Grisham M.B., Palombella V.J., Elliott P.J., Conner E.M., Brand S., Wong H.L., Pien C., Mazzola L.M., Destree A., Parent L., Adams J. Inhibition of NF-kappa B activation in vitro and in vivo: role of 26S proteasome. Methods Enzymol. 1999, 300:345-363.
34. Haasbach E., Pauli E.K., Spranger R., Mitzner D., Schubert U., Kircheis R., Planz O. Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses. Antiviral Res.. 2011, 91:304-313.
35. Haasbach E., Hartmayer C., Planz O. Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro. Antiviral Res.. 2013, 98:319-324.
36. Haura E.B., Ricart A.D., Larson T.G., Stella P.J., Bazhenova L., Miller V.A., Cohen R.B., Eisenberg P.D., Selaru P., Wilner K.D., Gadgeel S.M. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 2010, 16:2450-2457.
37. Hoffmann A., Natoli G., Ghosh G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene 2006, 25:6706-6716.
38. Hoffmann H.H., Palese P., Shaw M.L. Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity. Antiviral Res.. 2008, 80:124-134.
39. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
40. Iqbal M., Chatterjee S., Kauer J.C., Das M., Messina P., Freed B., Biazzo W., Siman R. Potent inhibitors of proteasome. J. Med. Chem. 1995, 38:2276-2277.
41. Iverson C., Larson G., Lai C., Yeh L.T., Dadson C., Weingarten P., Appleby T., Vo T., Maderna A., Vernier J.M., Hamatake R., Miner J.N., Quart B. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009, 69:6839-6847.
42. Jobin C., Hellerbrand C., Licato L.L., Brenner D.A., Sartor R.B. Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors. Gut 1998, 42:779-787.
43. Kane R.C., Farrell A.T., Sridhara R., Pazdur R. United States food and drug administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res. 2006, 12:2955-2960.
44. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 2000, 18:621-663.
45. Kramer A., Liashkovich I., Oberleithner H., Ludwig S., Mazur I., Shahin V. Apoptosis leads to a degradation of vital components of active nuclear transport and a dissociation of the nuclear lamina. Proc. Natl. Acad. Sci. USA 2008, 105:11236-11241.
46. Kumar N., Xin Z.T., Liang Y., Ly H. NF-kappaB signaling differentially regulates influenza virus RNA synthesis. J. Virol. 2008, 82:9880-9889.
47. Kurtz J.E., Ray-Coquard I. PI3 kinase inhibitors in the clinic: an update. Anticancer Res 2012, 32:2463-2470.
48. Leban J., Baierl M., Mies J., Trentinaglia V., Rath S., Kronthaler K., Wolf K., Gotschlich A., Seifert M.H. A novel class of potent NF-kappaB signaling inhibitors. Bioorg. Med. Chem. Lett. 2007, 17:5858-5862.
49. Lorusso P.M., Adjei A.A., Varterasian M., Gadgeel S., Reid J., Mitchell D.Y., Hanson L., DeLuca P., Bruzek L., Piens J., Asbury P., Van Becelaere K., Herrera R., Sebolt-Leopold J., Meyer M.B. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. 2005, 23:5281-5293.
50. Ludwig S. Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J. Antimicrob. Chemother. 2009, 64:1-4.
51. Ludwig S., Planz O. Influenza viruses and the NF-kappaB signaling pathway - towards a novel concept of antiviral therapy. Biol. Chem. 2008, 389:1307-1312.
52. Ludwig S., Planz O., Pleschka S., Wolff T. Influenza-virus-induced signaling cascades: targets for antiviral therapy?. Trends Mol. Med. 2003, 9:46-52.
53. Ludwig S., Wolff T., Ehrhardt C., Wurzer W.J., Reinhardt J., Planz O., Pleschka S. MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. FEBS Lett. 2004, 561:37-43.
54. Ludwig S., Pleschka S., Planz O., Wolff T. Ringing the alarm bells: signalling and apoptosis in influenza virus infected cells. Cell Microbiol. 2006, 8:375-386.
55. Ma X.Z., Bartczak A., Zhang J., Khattar R., Chen L., Liu M.F., Edwards A., Levy G., McGilvray I.D. Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome. J. Virol. 2010, 84:12419-12428.
56. Mackay H., Hedley D., Major P., Townsley C., Mackenzie M., Vincent M., Degendorfer P., Tsao M.S., Nicklee T., Birle D., Wright J., Siu L., Moore M., Oza A. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin. Cancer Res. 2005, 11:5526-5533.
57. Mahmoudian S., Auerochs S., Grone M., Marschall M. Influenza A virus proteins PB1 and NS1 are subject to functionally important phosphorylation by protein kinase C. J. Gen. Virol. 2009, 90:1392-1397.
58. Maira S.M., Finan P., Garcia-Echeverria C. From the bench to the bed side: PI3K pathway inhibitors in clinical development. Curr. Top. Microbiol. Immunol. 2010, 347:209-239.
59. Marjuki H., Alam M.I., Ehrhardt C., Wagner R., Planz O., Klenk H.D., Ludwig S., Pleschka S. Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Calpha-mediated activation of ERK signaling. J. Biol. Chem. 2006, 281:16707-16715.
60. Marjuki H., Yen H.L., Franks J., Webster R.G., Pleschka S., Hoffmann E. Higher polymerase activity of a human influenza virus enhances activation of the hemagglutinin-induced Raf/MEK/ERK signal cascade. Virol. J. 2007, 4:134.
61. Mazur I., Wurzer W.J., Ehrhardt C., Pleschka S., Puthavathana P., Silberzahn T., Wolff T., Planz O., Ludwig S. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol. 2007, 9:1683-1694.
62. Mitzner D., Dudek S.E., Studtrucker N., Anhlan D., Mazur I., Wissing J., Jansch L., Wixler L., Bruns K., Sharma A., Wray V., Henklein P., Ludwig S., Schubert U. Phosphorylation of the influenza A virus protein PB1-F2 by PKC is crucial for apoptosis promoting functions in monocytes. Cell Microbiol. 2009, 11:1502-1516.
63. Mizumura K., Hashimoto S., Maruoka S., Gon Y., Kitamura N., Matsumoto K., Hayashi S., Shimizu K., Horie T. Role of mitogen-activated protein kinases in influenza virus induction of prostaglandin E2 from arachidonic acid in bronchial epithelial cells. Clin. Exp. Allergy 2003, 33:1244-1251.
64. Nakayama T., Yamashita M. The TCR-mediated signaling pathways that control the direction of helper T cell differentiation. Semin. Immunol. 2010, 22:303-309.
65. Nimmerjahn F., Dudziak D., Dirmeier U., Hobom G., Riedel A., Schlee M., Staudt L.M., Rosenwald A., Behrends U., Bornkamm G.W., Mautner J. Active NF-kappaB signalling is a prerequisite for influenza virus infection. J. Gen. Virol. 2004, 85:2347-2356.
66. O'Connor O.A., Wright J., Moskowitz C., Muzzy J., MacGregor-Cortelli B., Stubblefield M., Straus D., Portlock C., Hamlin P., Choi E., Dumetrescu O., Esseltine D., Trehu E., Adams J., Schenkein D., Zelenetz A.D. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncol. 2005, 23:676-684.
67. Olschlager V., Pleschka S., Fischer T., Rziha H.J., Wurzer W., Stitz L., Rapp U.R., Ludwig S., Planz O. Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice. Oncogene 2004, 23:6639-6646.
68. Orlowski J.P., Hanhan U.A., Fiallos M.R. Is aspirin a cause of Reye's syndrome? A case against. Drug Safety 2002, 25:225-231.
69. Orlowski R.Z., Voorhees P.M., Garcia R.A., Hall M.D., Kudrik F.J., Allred T., Johri A.R., Jones P.E., Ivanova A., Van Deventer H.W., Gabriel D.A., Shea T.C., Mitchell B.S., Adams J., Esseltine D.L., Trehu E.G., Green M., Lehman M.J., Natoli S., Collins J.M., Lindley C.M., Dees E.C. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005, 105:3058-3065.
70. Ott D.E., Coren L.V., Chertova E.N., Gagliardi T.D., Nagashima K., Sowder R.C., Poon D.T., Gorelick R.J. Elimination of protease activity restores efficient virion production to a human immunodeficiency virus type 1 nucleocapsid deletion mutant. J. Virol 2003, 77:5547-5556.
71. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
72. Palombella V.J., Rando O.J., Goldberg A.L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78:773-785.
73. Papandreou C.N., Daliani D.D., Nix D., Yang H., Madden T., Wang X., Pien C.S., Millikan R.E., Tu S.M., Pagliaro L., Kim J., Adams J., Elliott P., Esseltine D., Petrusich A., Dieringer P., Perez C., Logothetis C.J. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. 2004, 22:2108-2121.
74. Pauli E.K., Schmolke M., Wolff T., Viemann D., Roth J., Bode J.G., Ludwig S. Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. PLoS Pathog. 2008, 4:e1000196.
75. Perkins N.D. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 2006, 25:6717-6730.
76. Pinto R., Herold S., Cakarova L., Hoegner K., Lohmeyer J., Planz O., Pleschka S. Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo. Antiviral Res. 2011, 92:45-56.
77. Planz O., Pleschka S., Ludwig S. MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells. J. Virol. 2001, 75:4871-4877.
78. Pleschka S. RNA viruses and the mitogenic Raf/MEK/ERK signal transduction cascade. Biol. Chem. 2008, 389:1273-1282.
79. Pleschka S., Wolff T., Ehrhardt C., Hobom G., Planz O., Rapp U.R., Ludwig S. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat. Cell Biol. 2001, 3:301-305.
80. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., Siegel D., Orlowski R.Z., Kuter D., Limentani S.A., Lee S., Hideshima T., Esseltine D.L., Kauffman M., Adams J., Schenkein D.P., Anderson K.C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348:2609-2617.
81. Rinehart J., Adjei A.A., Lorusso P.M., Waterhouse D., Hecht J.R., Natale R.B., Hamid O., Varterasian M., Asbury P., Kaldjian E.P., Gulyas S., Mitchell D.Y., Herrera R., Sebolt-Leopold J.S., Meyer M.B. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 2004, 22:4456-4462.
82. Ruckle A., Haasbach E., Julkunen I., Planz O., Ehrhardt C., Ludwig S. The NS1 protein of influenza A virus blocks RIG-I-mediated activation of the noncanonical NF-kappaB pathway and p52/RelB-dependent gene expression in lung epithelial cells. J. Virol. 2012, 86:10211-10217.
83. Russo A., Bronte G., Fulfaro F., Cicero G., Adamo V., Gebbia N., Rizzo S. Bortezomib: a new pro-apoptotic agent in cancer treatment. Curr. Cancer Drug Targets 2010, 10:55-67.
84. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., Spicka I., Petrucci M.T., Palumbo A., Samoilova O.S., Dmoszynska A., Abdulkadyrov K.M., Schots R., Jiang B., Mateos M.V., Anderson K.C., Esseltine D.L., Liu K., Cakana A., van de Velde H., Richardson P.G. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 2008, 359:906-917.
85. Scheidereit C. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 2006, 25:6685-6705.
86. Schubert U., Ott D.E., Chertova E.N., Welker R., Tessmer U., Princiotta M.F., Bennink J.R., Krausslich H.G., Yewdell J.W. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc. Natl. Acad. Sci. USA 2000, 97:13057-13062.
87. Sebolt-Leopold J.S., Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 2004, 4:937-947.
88. Seth R.B., Sun L., Chen Z.J. Antiviral innate immunity pathways. Cell Res. 2006, 16:141-147.
89. Shi X., Ding M., Dong Z., Chen F., Ye J., Wang S., Leonard S.S., Castranova V., Vallyathan V. Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production. Mol. Cell Biochem. 1999, 199:93-102.
90. Shin Y.K., Li Y., Liu Q., Anderson D.H., Babiuk L.A., Zhou Y. SH3 binding motif 1 in influenza A virus NS1 protein is essential for PI3K/Akt signaling pathway activation. J. Virol. 2007, 81:12730-12739.
91. Shin Y.K., Liu Q., Tikoo S.K., Babiuk L.A., Zhou Y. Effect of the phosphatidylinositol 3-kinase/Akt pathway on influenza A virus propagation. J. Gen. Virol. 2007, 88:942-950.
92. Sieczkarski S.B., Brown H.A., Whittaker G.R. Role of protein kinase C betaII in influenza virus entry via late endosomes. J. Virol. 2003, 77:460-469.
93. Smith J.R., Rayner C.R., Donner B., Wollenhaupt M., Klumpp K., Dutkowski R. Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience. Adv. Ther. 2011, 28:927-959.
94. Utecht K.N., Kolesar J. Bortezomib: a novel chemotherapeutic agent for hematologic malignancies. Am. J. Health Syst. Pharm. 2008, 65:1221-1231.
95. Vanhaesebroeck B., Ali K., Bilancio A., Geering B., Foukas L.C. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 2005, 30:194-204.
96. Visekruna A., Volkov A., Steinhoff U. A key role for NF-kappaB transcription factor c-Rel in T-lymphocyte-differentiation and effector functions. Clin. Dev. Immunol. 2012, 2012:239368.
97. Wallace, E.M., Lyssikatos, J., Blake, J.F., Marlow, A., Greschuk, J., Yeh, T.C., Callejo, M., Marsh, V., Poch, G., Winkler, J.J., Koch, K., Davies, B.R., Wilkinson, R.W., Jones, D.C., Logie, A., McKay, J., Smith, P.D., Robinson, D.T., 2009. AZD8330 (ARRY-424704): Preclinical Evaluation of a Potent, Selective MEK 1/2 Inhibitor Currently in Phase I Trails. AACR 100th Annual Meeting, Denver, USA, 18th-22nd April.
98. Wei L., Sandbulte M.R., Thomas P.G., Webby R.J., Homayouni R., Pfeffer L.M. NFkappaB negatively regulates interferon-induced gene expression and anti-influenza activity. J. Biol. Chem. 2006, 281:11678-11684.
99. Widjaja I., de Vries E., Tscherne D.M., Garcia-Sastre A., Rottier P.J., de Haan C.A. Inhibition of the ubiquitin-proteasome system affects influenza A virus infection at a postfusion step. J. Virol. 2010, 84:9625-9631.
100. Widmann C., Gibson S., Jarpe M.B., Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. 1999, 79:143-180.
101. Wurzer W.J., Planz O., Ehrhardt C., Giner M., Silberzahn T., Pleschka S., Ludwig S. Caspase 3 activation is essential for efficient influenza virus propagation. Embo. J. 2003, 22:2717-2728.
102. Wurzer W.J., Ehrhardt C., Pleschka S., Berberich-Siebelt F., Wolff T., Walczak H., Planz O., Ludwig S. NF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation. J. Biol. Chem. 2004, 279:30931-30937.
103. Yeh T.C., Marsh V., Bernat B.A., Ballard J., Colwell H., Evans R.J., Parry J., Smith D., Brandhuber B.J., Gross S., Marlow A., Hurley B., Lyssikatos J., Lee P.A., Winkler J.D., Koch K., Wallace E. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 2007, 13:1576-1583.
104. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396:77-80.
105. Zeng Z., Lin J., Chen J. Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Ann. Hematol. 2013, 23:1-2. 2013 Mar 2. [Epub ahead of print].
106. Zhirnov O.P., Klenk H.D. Control of apoptosis in influenza virus-infected cells by up-regulation of Akt and p53 signaling. Apoptosis 2007, 12:1419-1432.
107. Zhou Z., Jiang X., Liu D., Fan Z., Hu X., Yan J., Wang M., Gao G.F. Autophagy is involved in influenza A virus replication. Autophagy 2009, 5:321-328.